A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
← catalyst calendarNCT06697184 · readout in 1,199 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
258estimated
Sites
17
Countries
Australia, France, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-23 | actual | When the study began enrolling |
| Primary completion | 2029-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- CLL
- Mantle Cell Lymphoma
- MCL
Interventions
- Drug: Sonrotoclax — also filed as BGB-11417
- Drug: Zanubrutinib — also filed as BGB-3111
Primary outcome
what the primary-completion date above is the date OFNumber of Participants who Experience Tumor Lysis Syndrome (TLS)
measured Up to approximately 4 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed